Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $29,527.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $23.25, for a total transaction of $29,527.50. Following the sale, the director now directly owns 130,373 shares of the company’s stock, valued at approximately $3,031,172.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Stock Up 6.1 %

Shares of Enliven Therapeutics stock opened at $23.67 on Thursday. The business has a 50 day moving average of $22.94 and a 200 day moving average of $20.28. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $27.67. The company has a market cap of $1.11 billion, a PE ratio of -12.26 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ELVN shares. Robert W. Baird began coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective on the stock. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Institutional Trading of Enliven Therapeutics

Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the period. First Turn Management LLC bought a new position in Enliven Therapeutics in the second quarter worth $9,657,000. Marshall Wace LLP bought a new position in Enliven Therapeutics in the second quarter worth $4,489,000. Baker BROS. Advisors LP purchased a new position in Enliven Therapeutics during the first quarter valued at $2,020,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after buying an additional 37,632 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.